Generics growth and innovation in pharmaceuticals

The U.S. pharmaceutical market highlights a striking pattern: both generics and original drugs grow when the market expands, but their pace and mechanics differ. Here, demographics, regulations, and institutional rules play a decisive role. They shape not only how quickly new drugs appear but also which type takes the lead.

The main difference is speed. Generics grow faster. Their production is cheaper and simpler. Developing an original medicine takes years of research, costly clinical trials, and investments running into hundreds of millions of dollars. A generic requires far less: once a patent expires, companies can prove equivalence and quickly enter the market. In the U.S., the Hatch-Waxman Act of 1984 made this process much easier. Approval costs dropped dramatically, turning generics into the pharmaceutical industry’s “quick response” to growing demand.

Still, original innovations have not disappeared. Companies continue to invest in new molecules when the market is big enough to cover the high costs. Otherwise, the project simply isn’t worth it. As a result, original drugs tend to appear in areas where demand is steady and rising, such as chronic disease treatments and oncology for an aging population.

Economic models explain this well: both generics and originals depend on market size, but their sensitivity is different. Generics react sharply and quickly because entry barriers are low. Originals move more slowly, as decisions on new drugs are made with a 10–15-year horizon. This means the future of innovation is tied to demographic changes expected over the coming decades.

The patent system also matters. If protection is too strong and lasts too long, companies hold monopolies and slow down the spread of generics. If protection is too weak, firms lose incentives to invest in new medicines because cheap copies will soon eat into their profits. The right balance is crucial: rules must support both expensive original research and affordable generics.

For Kazakhstan, this debate is very relevant. Today the domestic market is heavily dependent on imports, and generics dominate pharmacy shelves. This is natural for a relatively small market: developing original molecules at home is costly and risky. But demographic change is reshaping demand. As the share of older people grows, the need for chronic disease drugs, cardiovascular treatments, and cancer medicines will rise. The real question is who will meet this demand, and how.

Kazakhstan could pursue a dual strategy. On one side, encourage local generic production to ensure affordability and reduce dependence on imports. This creates a base for the industry. On the other, start building capacity for original research-even if only partially-through joint projects, clinical trials, or local R&D partnerships with international firms. Tax incentives, state programs, and foreign cooperation can play an important role here.

From an economic perspective, generics will always grow faster, especially in small markets. But without original research, the industry risks staying dependent. This is why Kazakhstan should use demographic forecasts as a planning tool. If it’s clear that by 2030 the share of older people will rise sharply, then support for that segment must begin now. This ensures growth both in generics and in targeted original development.

In the end, generics and originals are not rivals-they are two different responses to the same market forces. Generics provide quick and affordable access, while originals deliver long-term innovation and resilience. For Kazakhstan, success depends on balancing both. With the right mix, the country can move from being a consumer of global pharma to a contributor with its own solutions.